Regeneron leads concentrated interleukin inhibitors market

By AI, Created 11:45 AM UTC, May 20, 2026, /AGP/ – The interleukin inhibitors market is highly concentrated, with the top 10 companies controlling 84% of revenue in 2024, according to The Business Research Company. Regeneron Pharmaceuticals and Sanofi each held 17% shares, while Boehringer Ingelheim pushed a new IL-11 candidate into Phase II testing in January 2026.

Why it matters: - The interleukin inhibitors market is being shaped by a small group of large drugmakers with deep biologics capabilities. - High concentration signals strong barriers to entry, including clinical trial demands, drug approvals, manufacturing complexity and heavy R&D spending. - Growth in autoimmune, inflammatory and fibrotic disease treatments is pushing companies toward new biologics, biosimilars and next-generation immunology assets.

What happened: - The Business Research Company said Regeneron Pharmaceuticals Inc. led global interleukin inhibitors sales in 2024 with a 17% market share. - Sanofi S.A. also held a 17% share, followed by Johnson & Johnson Services Inc. at 16% and AbbVie Inc. at 13%. - Novartis International AG held 9% of the market. - F. Hoffmann-La Roche Ltd and Eli Lilly and Company each held 4%. - GlaxoSmithKline Plc held 3%. - AstraZeneca Plc held 2%. - UCB held 1%. - The top 10 players accounted for 84% of total market revenue in 2024. - The report lists Regeneron, Sanofi, Johnson & Johnson, AbbVie, Novartis, Roche, Eli Lilly, GlaxoSmithKline, AstraZeneca and UCB as the leading companies. - Boehringer Ingelheim advanced BI 765423, an investigational IL-11 inhibitor, into Phase II trials in January 2026 for idiopathic pulmonary fibrosis. - The Business Research Company published the market report as a 2026 outlook covering the market through 2035.

The details: - The report says leading companies compete through advanced monoclonal antibody therapies, targeted immunomodulatory treatments, precision biologic drug development and tighter regulatory and clinical compliance frameworks. - Competitive positioning also depends on clinical efficacy, safety outcomes, advanced biologics manufacturing and data-driven clinical research systems. - Regeneron’s immunology and inflammation division offers monoclonal antibody therapies and targeted biologic treatments for inflammatory and autoimmune conditions. - The report names a wide group of other major market participants, including Merck & Co. Inc, Takeda Pharmaceutical Company Limited, Biogen Inc, Astellas Pharma Inc, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd and Sun Pharmaceutical Industries. - Major raw material suppliers include Thermo Fisher Scientific, Merck KGaA, Lonza, Sartorius, Cytiva, Fujifilm Diosynth Biotechnologies, Wuxi AppTec, Samsung Biologics, Catalent and AGC Biologics. - Major wholesalers and distributors include McKesson, Cardinal Health, Cencora, Zuellig Pharma, Phoenix Group Holdings, Medipal Holdings, Sinopharm, Shanghai Pharmaceuticals, DKSH and Morris & Dickson. - Major end users include AbbVie, Novartis, Johnson & Johnson, Eli Lilly, AstraZeneca, Roche, Bristol-Myers Squibb, Amgen, Sanofi, UCB and Pfizer. - The report highlights four current strategy themes: advancing interleukin inhibitors for chronic and immune diseases, monoclonal antibody biosimilars targeting IL-6, IL-23 inhibitors for Crohn’s disease and dual IL-17A/IL-17F inhibitors for hidradenitis suppurativa. - The report also provides a sample request link: Request a free sample. - The full report is available here: Access the detailed market report.

Between the lines: - The concentration of revenue among a handful of companies suggests innovation alone is not enough; scale, regulatory execution and manufacturing capacity remain decisive. - BI 765423’s move into Phase II reflects a broader push into less crowded cytokine targets, where companies can seek first-in-class differentiation. - The emphasis on biosimilars and specialty indications points to two parallel plays: widen access in established targets and build pricing power in more novel ones.

What’s next: - The market is expected to keep leaning on product innovation, regional expansion and strategic collaborations. - Clinical data from BI 765423 and other pipeline assets will help show whether newer interleukin targets can deliver measurable gains in fibrotic and inflammatory diseases. - Competitive pressure is likely to stay high as major drugmakers defend share and smaller biotech firms look for niche openings.